Distinct roles for type I and type III interferons in virulent human metapneumovirus pathogenesis

被引:3
|
作者
Zhang, Yu [1 ]
Xu, Jiuyang [1 ,2 ]
Miranda-Katz, Margot [1 ]
Sojati, Jorna [1 ]
Tollefson, Sharon J. [3 ]
Manni, Michelle L. [1 ]
Alcorn, John F. [1 ]
Sarkar, Saumendra N. [4 ]
Williams, John V. [1 ,4 ,5 ]
机构
[1] Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15260 USA
[2] Tsinghua Univ, Sch Med, Beijing, Peoples R China
[3] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN USA
[4] Univ Pittsburgh, Dept Microbiol & Mol Genet, Sch Med, Pittsburgh, PA 15260 USA
[5] Univ Pittsburgh, Inst Infect Inflammat & Immun Children i4Kids, Pittsburgh, PA 15224 USA
关键词
RESPIRATORY SYNCYTIAL VIRUS; TRACT INFECTIONS; REQUIRING HOSPITALIZATION; HUMAN PNEUMOVIRUS; DENDRITIC CELLS; YOUNG-CHILDREN; COTTON RAT; DISEASE; MODEL; REPLICATION;
D O I
10.1371/journal.ppat.1011840
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human metapneumovirus (HMPV) is an important cause of acute lower respiratory infection in children and adults worldwide. There are four genetic subgroups of HMPV and both neutralizing antibodies and T cells contribute to protection. However, little is known about mechanisms of pathogenesis and most published work is based on a few extensively passaged, laboratory-adapted strains of HMPV. In this study, we isolated and characterized a panel of low passage HMPV clinical isolates representing all four genetic subgroups. The clinical isolates exhibited lower levels of in vitro replication compared to a lab-adapted strain. We compared disease phenotypes using a well-established mouse model. Several virulent isolates caused severe weight loss, lung pathology, airway dysfunction, and fatal disease in mice, which was confirmed in three inbred mouse strains. Disease severity did not correlate with lung viral titer, as virulent strains exhibited restricted replication in the lower airway. Virulent HMPV isolates were associated with markedly increased proinflammatory cytokine production and neutrophil influx; however, depletion of neutrophils or genetic ablation of inflammasome components did not reverse disease. Virulent clinical isolates induced markedly increased type I and type III IFN (IFN) secretion in vitro and in vivo. STAT1/2-deficient mice lacking both type I and type III IFN signaling showed reduced disease severity and increased lung viral replication. Inhibition of type I IFN signaling using a blocking antibody or genetic ablation of the type I IFN receptor reduced pathology with minimal effect on viral replication. Conversely, blockade of type III IFN signaling with a neutralizing antibody or genetic ablation of the IFN-lambda receptor had no effect on pathogenesis but restored viral replication. Collectively, these results demonstrate distinct roles for type I and type III IFN in HMPV pathogenesis and immunity. Human metapneumovirus (HMPV) is a leading cause of acute lower respiratory infection in children and adults worldwide. However, little is known about mechanisms of pathogenesis and most published studies use a few laboratory-adapted strains of HMPV. In this study, we isolated and characterized disease phenotypes of a panel of HMPV isolates. We identified several virulent isolates capable of causing severe and fatal disease in mice. Virulent HMPV isolates were associated with markedly increased proinflammatory cytokine production as well as increased type I and type III IFN (IFN) secretion in vitro and in vivo. Inhibition of type I IFN signaling reduced pathology with minimal effect on viral replication. Conversely, blockade or genetic ablation of type III IFN signaling had no effect on pathogenesis but restored viral replication. Collectively, these results demonstrate distinct roles for type I and type III IFN in HMPV defense and disease.
引用
收藏
页数:25
相关论文
共 50 条
  • [41] Antitumor activity of Type I and Type III interferons in BNL hepatoma model
    Walid Abushahba
    Murugabaskar Balan
    Ismael Castaneda
    Yao Yuan
    Kenneth Reuhl
    Elizabeth Raveche
    Andrew de la Torre
    Ahmed Lasfar
    Sergei V. Kotenko
    Cancer Immunology, Immunotherapy, 2010, 59 : 1059 - 1071
  • [42] Differential signaling by type-I and type-III interferons in mucosa
    Stanifer, Megan L.
    Boulant, Steeve
    CURRENT OPINION IN IMMUNOLOGY, 2024, 86
  • [43] Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines
    Ye, Liang
    Ohnemus, Annette
    Ong, Li Ching
    Gad, Hans Henrik
    Hartmann, Rune
    Lycke, Nils
    Staeheli, Peter
    JOURNAL OF VIROLOGY, 2019, 93 (23)
  • [44] Human metapneumovirus blocks the induction of type I interferon
    van den Hoogen, B.
    Zahira, M.
    van Hagen, F.
    Andeweg, A.
    Osterhaus, A.
    Fouchier, R.
    CYTOKINE, 2009, 48 (1-2) : 136 - 136
  • [45] Type I and type III interferons display different dependency on MAPKs to mount an antiviral state in the human gut
    Stanifer, Megan L.
    Pervolaraki, Kalliopi
    Albrecht, Dorothee
    Renn, Lynnsey
    Rabin, Ronald
    Boulant, Steeve
    CYTOKINE, 2017, 100 : 154 - 154
  • [46] The Significance of Type-I Interferons in the Pathogenesis and Therapy of Human Immunodeficiency Virus 1 Infection
    Wang, Bowen
    Kang, Wen
    Zuo, Jiahui
    Kang, Wenzhen
    Sun, Yongtao
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [47] Differential Induction of Type I and III Interferons by Staphylococcus aureus
    Peignier, Adeline
    Planet, Paul J.
    Parker, Dane
    INFECTION AND IMMUNITY, 2020, 88 (10)
  • [48] The role of interferons type I, II and III in myositis: A review
    Bolko, Lois
    Jiang, Wei
    Tawara, Nozomu
    Landon-Cardinal, Oceane
    Anquetil, Celine
    Benveniste, Olivier
    Allenbach, Yves
    BRAIN PATHOLOGY, 2021, 31 (03)
  • [49] Differential Activation of the Transcription Factor IRF1 Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons
    Forero, Adriana
    Ozarkar, Snehal
    Li, Hongchuan
    Lee, Chia Heng
    Hemann, Emily A.
    Nadjsombati, Marija S.
    Hendricks, Matthew R.
    So, Lomon
    Green, Richard
    Roy, Chandra N.
    Sarkar, Saumendra N.
    von Moltke, Jakob
    Anderson, Stephen K.
    Gale, Michael, Jr.
    Savan, Ram
    IMMUNITY, 2019, 51 (03) : 451 - +
  • [50] The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19
    Schreiber, Gideon
    FRONTIERS IN IMMUNOLOGY, 2020, 11